Key result
Renin-angiotensin-aldosterone-system blockade is highlighted as a potential therapeutic option to target atrial structural remodelling underlying the development of atrial fibrillation.
Why the study?
Does renin-angiotensin-aldosterone-system blockade improve outcomes in patients with atrial fibrillation?
Does renin-angiotensin-aldosterone-system blockade improve outcomes in patients with atrial fibrillation?
This review highlights the potential of targeting atrial structural remodeling via RAAS blockade as a therapeutic strategy for atrial fibrillation, shifting focus from purely electrical therapies.
Despite its increasing incidence and prevalence, treatment options in atrial fibrillation (AF) are far from ideal and often limited. After decades of focus on the electrical aspects of AF with unsatisfactory results, recent research is focusing increasingly on the atrial structural remodelling that underlies the development of AF in different pathological conditions, such as hypertension, heart failure, diabetes mellitus and coronary artery disease. The aim of this review is to provide a comprehensive overview of the role of the renin-angiotensin-aldosterone-system in AF and to highlight the clinical evidence on renin-angiotensin-aldosterone-system blockade as a therapeutic option in AF.
No takes yet. Share an insight, caveat, or question.
Choudhury et al. (2005) conducted a review in Atrial fibrillation. Renin-angiotensin-aldosterone-system blockade was evaluated. Renin-angiotensin-aldosterone-system blockade is highlighted as a potential therapeutic option to target atrial structural remodelling underlying the development of atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: